Molecular markers, such as O6-methylguanine-DNA methyltransferase (MGMT) methylation, codeletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p/19q), mutations in isocitrate dehydrogenase (IDH), mutations in alpha thalassemia/mental retardation syndrome X-linked, and epidermal growth factor receptor are being used in molecular pathological diagnosis, treatment options, and prognostic evaluation with glioma patients (Zeng et al., 2015). Here, MGMT is linked to glioma.